XXII 22nd Century Group Inc.

22nd Century Group’s (Nasdaq: XXII) VLN® Cigarettes with Reduced Nicotine Technology Ready to Ignite Biden’s Cancer Moonshot Initiative

22nd Century Group’s (Nasdaq: XXII) VLN® Cigarettes with Reduced Nicotine Technology Ready to Ignite Biden’s Cancer Moonshot Initiative

  • Aligned with FDA and Biden Administration Important Initiative to Limit Nicotine Content in Cigarettes and Ban Menthol
  • VLN® Reduced Nicotine Content Cigarettes Are Designed Specifically to “” and Reduce Exposure to Activities Known to Cause Cancer
  • Exceptional Pilot Results in Chicago Lead to Expanding VLN® Points of Sale in Chicago and State of Illinois

BUFFALO, N.Y., Sept. 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that it is engaged to power President Biden’s plan to reduce the death rate from cancer by at least 50% over the next 25 years. The Company’s are the first and only combustible cigarette designed specifically to “”, which the U.S. Food and Drug Administration (FDA) to be printed right on the packaging. 22nd Century is expanding VLN® points of sale in Chicago and the State of Illinois after seeing exceptional pilot results in Chicagoland. Distribution will begin in September through various channels via retail and distribution partnerships.

Under Biden’s initiative, the FDA has taken aggressive actions aimed at curtailing smoking, in particular the Agency’s pursuit to limit the amount of nicotine and ban menthol-flavored cigarettes. Every year, nearly 500,000 Americans die from smoking-related diseases. Smoking is the leading cause of cancer deaths, with more than 160,000 people perishing every year from cancers directly attributed to tobacco. Although nicotine itself is not the direct cause of most smoking-related diseases, addiction to nicotine in tobacco is the proximate cause of smoking related diseases including cancer. Thus, the magnitude of public health harm that is caused by tobacco is inextricably linked to its addictive nature.

“It is well understood that addiction to nicotine is the primary driver of smoking, leading to smoking related diseases such as cancer. Rather than just another nicotine replacement therapy, 22nd Century’s VLN® cigarettes take a disruptive approach to help people smoke less by reducing the nicotine content to levels the FDA considers non-addictive. Numerous clinical studies sponsored by federal health agencies demonstrate that adult smokers can successfully smoke less and improve their health situation by using reduced nicotine cigarettes to first break the nicotine addiction cycle. By smoking less, adult smokers can reduce their exposure to activities known to cause cancer,” said James A. Mish, chief executive officer of 22nd Century Group.

FDA Commissioner Robert M. Califf explained at a last week that the Agency’s proposal to reduce nicotine content in cigarettes is based on nicotine’s extremely high addictive potential. He was quoted saying, “I think it’s every bit as strong as the opioid addiction.”

“Cancer doesn’t discriminate between red or blue, it doesn’t care if you’re a Republican or a Democrat,” said President Biden during his Moonshot Speech Monday afternoon. “Beating cancer is something we can do together and that’s why I’m here today.”

Biden’s Cancer Moonshot Initiative will bring together departments and agencies, including the National Institutes of Health (NIH), and the FDA, to address cancer on multiple fronts. These are the same government agencies that have funded numerous independent scientific studies demonstrating the of using reduced nicotine content tobacco cigarettes. 22nd Century’s VLN® King and VLN® Menthol King cigarettes were engineered to contain 95% less nicotine than conventional cigarettes and is the only combustible product that is in line with the FDA’s proposed nicotine cap. VLN® cigarettes smoke, smell, and taste like conventional cigarettes and are the only cigarettes in the world not designed to create or sustain nicotine addiction purposefully designed to “”.

FDA’s reduced nicotine mandate has the potential to help more than 5 million people quit smoking within the first year of implementation, prevent more than 33 million people from not becoming regular smokers, and prevent more than 8 million fewer people dying from tobacco-related illnesses, including cancer. The Agency also asserts that a proposed menthol ban is expected to have enormous health benefits for the nearly 20 million current smokers of menthol cigarettes. 22nd Century expects VLN® Menthol King reduced nicotine cigarettes to be exempted from FDA’s menthol ban under procedures detailed in announced April 28, 2022.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200

 



EN
13/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Group’s GVB Biopharma Opens New Central Distribution Faci...

22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands New distribution facility supports rapidly growing demand for hemp/cannabis products BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- , a 22nd Century Group company (Nasdaq: ), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon...

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022. “We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Inve...

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences: On Tuesday, November 15, 2022, the Company will host one-on-one meetings at the Roth 2nd Annual AgTech Answers Event.On Thursday, November 17, 2022, the Company will ho...

 PRESS RELEASE

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Fina...

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022 Accelerating VLN® Sales in Colorado and Illinois, Launching in Four Corners States to Capture Market Share and VolumeGVB Biopharma Acquisition Growing Revenue on Increased VolumesThird Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN® Expansion BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicate...

 PRESS RELEASE

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarett...

New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation Reduced nicotine cigarettes increase cessation, decrease consumption, decrease dependence, and reduce toxicantsStudy dispels common misconception that reduced nicotine cigarettes worsen general health and mental health problems BUFFALO, N.Y., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch